Ubs Group Ag Ventyx Biosciences, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 3,782,583 shares of VTYX stock, worth $5.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,782,583

Previous 1,197,386 215.9%

Holding current value

$5.75 Million

Previous $2.61 Million 217.36%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.72 - $3.12 $4.45 Million - $8.07 Million	2,585,197 Added 215.9%	3,782,583 $8.28 Million
Q3 2024 Nov 14, 2024	BUY	$1.85 - $3.2 $2.18 Million - $3.76 Million	1,175,766 Added 5438.33%	1,197,386 $2.61 Million
Q2 2024 Aug 13, 2024	SELL	$2.31 - $5.59 $87,546 - $211,855	-37,899 Reduced 63.68%	21,620 $49,000
Q1 2024 May 13, 2024	BUY	$1.9 - $10.13 $113,086 - $602,927	59,519 New	59,519 $327,000
Q3 2023 Nov 09, 2023	SELL	$29.8 - $40.3 $1.26 Million - $1.71 Million	-42,437 Reduced 99.55%	193 $6,000
Q2 2023 Aug 11, 2023	BUY	$28.53 - $39.55 $1.21 Million - $1.67 Million	42,346 Added 14910.56%	42,630 $1.4 Million
Q1 2023 May 12, 2023	SELL	$29.51 - $46.65 $27,886 - $44,084	-945 Reduced 76.89%	284 $9,000
Q4 2022 Feb 08, 2023	BUY	$24.16 - $36.38 $29,692 - $44,711	1,229 New	1,229 $40,000
Q2 2022 Aug 10, 2022	SELL	$11.95 - $18.75 $9,751 - $15,300	-816 Reduced 28.45%	2,052 $25,000
Q1 2022 May 16, 2022	SELL	$10.0 - $19.98 $9,320 - $18,621	-932 Reduced 24.53%	2,868 $39,000
Q4 2021 Feb 14, 2022	BUY	$14.2 - $23.07 $53,960 - $87,666	3,800 New	3,800 $76,000

Others Institutions Holding VTYX

# of Institutions

134

Shares Held

55.2M

Call Options Held

81.4K

Put Options Held

148K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $85.9M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account